Morepen Bags ₹825 Crore Global CDMO Deal; Shares Jump 14.78% as Stock Hits ₹45.33

Mumbai, February 23, 2026: Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has secured a multi-year Contract Development and Manufacturing Organization mandate valued at approximately ₹825 crore, marking one of the largest single CDMO engagements in its history. The announcement triggered strong investor response, with the stock rallying 14.78 percent to ₹45.03 in early trade.
As of 09:42 AM IST, the stock was trading at ₹45.03, up ₹5.80 from the previous close of ₹39.23. The scrip touched an intraday high of ₹45.33 and a low of ₹41.51, with a volume-weighted average price of ₹43.75.

₹825 Crore Multi-Year Mandate From Global Pharma Major​

According to the company’s press communication dated February 23, 2026 , Morepen has secured a multi-year CDMO mandate worth approximately ₹825 crore, equivalent to USD 91 million, from a leading global pharmaceutical company.
Supplies under the contract are expected to commence within the next four to five months, with execution scheduled through Q1 of the following financial year, subject to customary operational processes. The engagement significantly strengthens Morepen’s positioning in the high-growth CDMO segment.
The company described the mandate as one of the most significant in its CDMO portfolio as it expands its global manufacturing footprint.

Strengthening Global Manufacturing Programs​

Morepen stated that its CDMO platform is built on over four decades of API manufacturing expertise and regulatory credibility. The company operates internationally accredited facilities, including approvals from USFDA, WHO-GMP, and EU authorities.
With integrated development-to-commercial manufacturing capabilities, the company is positioned to support complex scale-ups and structured, long-duration supply programs for regulated markets.
The company also indicated that it continues to evaluate capacity enhancement and technology investments aligned with its expanding CDMO opportunity pipeline.

Management Commentary​

Sushil Suri, Chairman and Managing Director, stated:

“This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record, and execution capabilities. Over the years, we have steadily strengthened our infrastructure and compliance depth, enabling participation in larger, long-duration global programs.”

Click to expand...

He added that CDMO represents a natural extension of the company’s established API strengths, creating additional avenues of scale and long-term value creation.
Kushal Suri, President – International Growth (API), highlighted that the company executed the program end-to-end with technical, regulatory, and commercial scale-up, delivering a solution built for quality, continuity, and scale. He emphasized that the outcome validates Morepen’s credibility in regulated markets and positions it for larger global opportunities.

Market Reaction​

The stock witnessed sharp buying interest following the announcement:
The order book data showed higher sell-side depth relative to bids at the time of reporting, though buying momentum pushed the stock near its session high.

About Morepen Laboratories Limited​

Morepen Laboratories Limited is a vertically integrated pharmaceutical and healthcare company delivering APIs, branded generics, medical devices, and consumer wellness products to over 90 countries. The company has significant installed API capacity and a glucometer user base of approximately 14 million. It operates manufacturing facilities with international approvals and continues to expand its global footprint across regulated markets.
The company is listed on the National Stock Exchange of India and BSE Limited under the symbols MOREPENLAB and 500288, respectively.